FTC Approves Final Order Preserving Competition for Generic Drugs that Treat Bacterial Infections and Ulcerative Colitis
Date
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Lupin’s proposed $850 million acquisition of Gavis would likely be anticompetitive...